Our findings reveal that Cdkn2a and Becn1 function as potent positive regulators of beige-to-white adipocyte transition, providing a potential therapeutic target for pharmacological intervention to combat the obesity epidemic and its related metabolic diseases. Here, CDKN2A is linked to metabolic disease.